FDA approves Lilly’s diabetes drug for weight management
Eli Lilly and Co.’s hot-selling diabetes drug, Mounjaro, will now be sold for a second use, chronic weight management, using a separate brand name, Zepbound.
Eli Lilly and Co.’s hot-selling diabetes drug, Mounjaro, will now be sold for a second use, chronic weight management, using a separate brand name, Zepbound.
Excluding nonrecurring items, the Indianapolis-based drugmaker posted adjusted earnings of 10 cents a share, beating Zacks consensus estimate of a loss of 11 cents a share.
Eli Lilly and Co. will study its blockbuster diabetes drug Mounjaro in combination with an experimental muscle-loss treatment as it searches for ways to help patients maintain muscle while losing weight.
Roche has come under pressure to improve its pipeline with medicines it can commercialize soon as a windfall of revenue from products used in the COVID-19 pandemic comes to an end.
The federal designation marks Indiana as a hub for biologics manufacturing. Biologics are medicines derived from biological sources and include vaccines, monoclonal antibodies, and immune modulators.
The drugmaker accused 11 companies of importing products that they say contain tirzepatide, the active ingredient in Mounjaro, while falsely implying that their products are associated with Eli Lilly or approved by the FDA.
According to the petition Courtney Anguiano knowingly conspired with seven other people to submit 189 false and fraudulent post-transaction reimbursement requests under three different Eli Lilly and Co. savings card programs.
The results, which were also presented Sunday at a medical conference, confirm that the drug made by Eli Lilly and Co. has the potential to be one of the most powerful medical treatments for obesity to date, outside experts said.
After a bruising, five-year fight that went all the way to the U.S. Supreme Court, hospitals across Indiana and the nation are in line for a huge payday.
Walmart Inc. says it’s already seeing an impact on shopping demand from people taking the diabetes drug Ozempic, Wegovy and other appetite-suppressing medications.
Eli Lilly and Co. is paying Indianapolis-based startup Point Biopharma $12.50 a share, an 85% premium over the company’s closing price on Monday of $6.68 a share.
Eli Lilly and Co. just hit another bump in the road in its quest to push deeper into treatments for skin diseases, the third setback this year for the Indianapolis-based drugmaker from the U.S Food and Drug Administration.
The decision represents a rare case of a judge overturning a jury verdict and is a major win for Lilly, which argued strenuously that its Emgality drug is substantially different than Anjovy, a drug sold by competitor Teva Pharmaceuticals.
The solar structures are designed to help generate power for the company and reduce its carbon footprint.
During the last nine years, the cumulative amount of AI investments across the pharma and biotech sectors has increased by almost thirtyfold, to $24.6 billion as of last December.
Lilly is suing medical spas, wellness centers and compounding pharmacies in various U.S. states that sell unapproved versions of its blockbuster diabetes drug, which is frequently used off-label for weight loss.
Following a $45 million renovation, RayzeBio plans to use the plant to make Actinium 225, a radioisotope used for targeted therapy for cancer.
Isotopia USA, the newly formed U.S. subsidiary of Isotopia Molecular Imaging, announced Monday that it will hire 50 people to produce a radioactive medical isotope used in pharmaceuticals for targeted cancer treatment.
The leading decongestant used by millions of Americans looking for relief from a stuffy nose is likely no better than a dummy pill, according to government experts.
If the Centers for Disease Control and Prevention signs off Tuesday, injections could be available in pharmacies, clinics and doctor’s offices by the end of the week.